Cannabinoids and psychosis

References

• Andreasson S, Allebeck P, Engstrom A, Rydberg U. Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 1987; 2: 1483–1486
   PubMed Web of Science ®Google Scholar
• Arendt M, Mortensen PB, Rosenberg R, Pedersen CB, Waltoft BL. Familial predisposition for psychiatric disorder: Comparison of subjects treated for cannabis-induced psychosis and schizophrenia. Arch Gen Psychiatry 2008; 65: 1269–1274
   PubMed Web of Science ®Google Scholar
• Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: Follow-up study of 535 incident cases. British Journal of Psychiatry 2005; 187: 510–515
   PubMed Web of Science ®Google Scholar
• Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE. Cannabis use in adolescence and risk for adult psychosis: Longitudinal prospective study. British Medical Journal 2002; 325: 1212–1213
   PubMed Web of Science ®Google Scholar
• Auclair N, Otani S, Soubrie P, Crepel F. Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons. Journal of Neurophysiology 2000; 83: 3287–3293
   PubMed Web of Science ®Google Scholar
• Aust R, Sharp C, Goulden C. Prevalence of drug use: Key findings from the 2001/2002 British Crime Survey, Findings 182. Home Office Research, Development and Statistics Directorate, London 2002
   Google Scholar
• Azad SC, Eder M, Marsicano G, Lutz B, Zieglgansberger W, Rammes G. Activation of the cannabinoid receptor type 1 decreases glutamatergic and GABAergic synaptic transmission in the lateral amygdala of the mouse. Learn Mem 2003; 10: 116–128
   PubMedGoogle Scholar
• Barkus E, Lewis S. Schizotypy and psychosis-like experiences from recreational cannabis in a non-clinical sample. Psychol Med 2008; 38: 1267–1276
   PubMed Web of Science ®Google Scholar
• Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology 2002; 59: 1337–1343
   PubMed Web of Science ®Google Scholar
• Bolla KI, Eldreth DA, Matochik JA, Cadet JL. Neural substrates of faulty decision-making in abstinent marijuana users. Neuroimage 2005; 26: 480–492
   PubMed Web of Science ®Google Scholar
• Bossong MG, van Berckel, Bart NM, Boellaard R, Zuurman L, Schuit RC, Windhorst AD, van Gerven JMA, Ramsey NF, Lammertsma AA, Kahn RS. Delta-9-Tetrahydrocannabinol Induces Dopamine Release in the Human Striatum
   Google Scholar
• Boucher AA, Arnold JC, Duffy L, Schofield PR, Micheau J, Karl T. Heterozygous neuregulin 1 mice are more sensitive to the behavioural effects of Delta9-tetrahydrocannabinol. Psychopharmacology Berlin 2007; 192: 325–336
   PubMedGoogle Scholar
• Butovsky E, Juknat A, Goncharov I, Elbaz J, Eilam R, Zangen A, et al. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Delta-tetrahydrocannabinol. Journal of Neurochem 2005; 93: 802–811
   PubMedGoogle Scholar
• Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington H, et al. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: Longitudinal evidence of a gene X environment interaction. Biol Psychiatry 2005; 57: 1117–1127
   PubMed Web of Science ®Google Scholar
• Chopra GS, Smith JW. Psychotic reactions following cannabis use in East Indians. Arch Gen Psychiatry 1974; 30: 24–27
   PubMed Web of Science ®Google Scholar
• Collip D, Myin-Germeys I, Van Os J. Does the concept of ‘sensitization' provide a plausible mechanism for the putative link between the environment and schizophrenia?. Schizophr Bull 2008; 34: 220–225
   PubMed Web of Science ®Google Scholar
• Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: Classification as cannabimimetic agents. Journal of Pharmacol Exp Ther 1992; 260: 201–209
   PubMed Web of Science ®Google Scholar
• Corcoran CM, Kimhy D, Stanford A, Khan S, Walsh J, Thompson J, Schobel S, Harkavy-Friedman J, Goetz R, Colibazzi T, Cressman V, Malaspina D. Temporal association of cannabis use with symptoms in individuals at clinical high risk for psychosis. Schizophr Res 2008; 106: 286–93
   PubMed Web of Science ®Google Scholar
• D'Souza DC. Cannabinoids and psychosis. Int Rev Neurobiol 2007; 78: 289–326
   PubMedGoogle Scholar
• D'Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, et al. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol Psychiatry 2005; 57: 594–608
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, et al. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Delta-9-tetrahydrocannabinol in humans. Psychopharmacology (Berlin) 2008a; 198: 587–603
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, et al. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004; 29: 1558–1572
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology (Berlin) 2008b; 202: 569–578
   PubMedGoogle Scholar
• Der G, Gupta S, Murray RM. Is schizophrenia disappearing?. Lancet 1990; 335: 513–516
   PubMed Web of Science ®Google Scholar
• Derkinderen P, Valjent E, Toutant M, Corvol JC, Enslen H, Ledent C. Regulation of extracellular signal-regulated kinase by cannabinoids in hippocampus. Journal of Neuroscience 2003; 23: 2371–2382
   PubMed Web of Science ®Google Scholar
• Diana M, Melis M, Gessa GL. Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. European Journal of Neuroscience 1998; 10: 2825–2830
   PubMed Web of Science ®Google Scholar
• Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. Journal of Neuroscience 2006; 26: 5794–5799
   PubMedGoogle Scholar
• Dumas P, Saoud M, Bouafia S, Gutknecht C, Ecochard R, Dalery J, et al. Cannabis use correlates with schizotypal personality traits in healthy students. Psychiatry Res 2002; 109: 27–35
   PubMed Web of Science ®Google Scholar
• Eggan SM, Lewis DA. Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: A regional and laminar analysis. Cerebral Cortex 2007; 17: 175–191
   PubMed Web of Science ®Google Scholar
• Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L, et al. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology (Berlin) 1999; 142: 295–301
   PubMed Web of Science ®Google Scholar
• Eldreth DA, Matochik JA, Cadet JL, Bolla KI. Abnormal brain activity in prefrontal brain regions in abstinent marijuana users. Neuroimage 2004; 23: 914–920
   PubMed Web of Science ®Google Scholar
• Elsohly MA, Slade D. Chemical constituents of marijuana: The complex mixture of natural cannabinoids. Life Sci 2005; 78: 539–548
   PubMed Web of Science ®Google Scholar
• Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006; 17: 1629–1632
   PubMed Web of Science ®Google Scholar
• Fried PA, Watkinson B, Gray R. Differential effects on cognitive functioning in 13- to 16-year-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 2003; 25: 427–436
   PubMed Web of Science ®Google Scholar
• Fried PA, Watkinson B, Gray R. Neurocognitive consequences of marihuana – A comparison with pre-drug performance. Neurotoxicol Teratol 2005; 27: 231–239
   PubMed Web of Science ®Google Scholar
• Fujiwara M, Egashira N. New perspectives in the studies on endocannabinoid and cannabis: Abnormal behaviors associate with CB1 cannabinoid receptor and development of therapeutic application. Journal of Pharmacol Sci 2004; 96: 362–366
   PubMed Web of Science ®Google Scholar
• Galve-Roperh I, Aguado T, Palazuelos J, Guzman M. The endocannabinoid system and neurogenesis in health and disease. Neuroscientist 2007; 13: 109–114
   PubMedGoogle Scholar
• Gardner EL. Endocannabinoid signaling system and brain reward: Emphasis on dopamine. Pharmacol Biochem Behav 2005; 81: 263–284
   PubMed Web of Science ®Google Scholar
• Goldman-Rakic PS. Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 1996; 93: 13473–13480
   PubMed Web of Science ®Google Scholar
• Goldschmidt L, Richardson GA, Cornelius MD, Day NL. Prenatal marijuana and alcohol exposure and academic achievement at age 10. Neurotoxicol Teratol 2004; 26: 521–532
   PubMed Web of Science ®Google Scholar
• Green B, Kavanagh D, Young R. Being stoned: A review of self-reported cannabis effects. Drug Alcohol Rev 2003; 22: 453–460
   PubMed Web of Science ®Google Scholar
• Hajos M, Hoffmann WE, Kocsis B. Activation of cannabinoid-1 receptors disrupts sensory gating and neuronal oscillation: Relevance to schizophrenia. Biol Psychiatry 2008; 63: 1075–1083
   PubMedGoogle Scholar
• Hajos N, Katona I, Naiem SS, MacKie K, Ledent C, Mody I, et al. Cannabinoids inhibit hippocampal GABAergic transmission and network oscillations. Eur J Neurosci 2000; 12: 3239–3249
   PubMed Web of Science ®Google Scholar
• Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 2001; 106: 1–4
   PubMed Web of Science ®Google Scholar
• Halikas JA, Goodwin DW, Guze SB. Pattern of marihuana use: A survey of one hundred regular users. Compr Psychiatry 1972; 13: 161–163
   PubMed Web of Science ®Google Scholar
• Hall W, Pacula R. Cannabis Use and dependence: Public health and public policy. Cambridge University Press, Cambridge 2003
   Google Scholar
• Hall W, Solowij N. Adverse effects of cannabis. Lancet 1998; 352: 1611–1616
   PubMed Web of Science ®Google Scholar
• Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: A quantitative review of the evidence. Neuropsychology 1998; 12: 426–445
   PubMed Web of Science ®Google Scholar
• Heishman SJ, Huestis MA, Henningfield JE, Cone EJ. Acute and residual effects of marijuana: Profiles of plasma THC levels, physiological, subjective, and performance measures. Pharmacol Biochem Behav 1990; 37: 561–565
   PubMed Web of Science ®Google Scholar
• Henquet C, Di Forti M, Morrison P, Kuepper R, Murray RM. Gene-environment interplay between cannabis and psychosis. Schizophr Bull 2008; 34: 1111–1121
   PubMed Web of Science ®Google Scholar
• Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU, et al. Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. British Medical Journal 2005a; 330: 11
   PubMed Web of Science ®Google Scholar
• Henquet C, Murray R, Linszen D, van Os J. The environment and schizophrenia: The role of cannabis use. Schizophr Bull 2005b; 31: 608–612
   PubMed Web of Science ®Google Scholar
• Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, et al. An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 2006; 31: 2748–2757
   PubMed Web of Science ®Google Scholar
• Henquet C, Van Os J. The coherence of the evidence linking cannabis with psychosis. Psychol Med 2008; 38: 461–462, author reply 462–464
   PubMedGoogle Scholar
• Hermann H, Marsicano G, Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002; 109: 451–460
   PubMed Web of Science ®Google Scholar
• Hoffman AF, Lupica CR. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J Neurosci 2000; 20: 2470–2479
   PubMed Web of Science ®Google Scholar
• Hollister LE. Cannabis – 1988. Acta Psychiatr Scand Suppl 1988; 345: 108–118
   PubMedGoogle Scholar
• Hooker WD, Jones RT. Increased susceptibility to memory intrusions and the Stroop interference effect during acute marijuana intoxication. Psychopharmacology (Berlin) 1987; 91: 20–24
   PubMedGoogle Scholar
• Iversen L. Cannabis and the brain. Brain 2003; 126: 1252–1270
   PubMed Web of Science ®Google Scholar
• Knudsen P, Vilmar T. Cannabis and neuroleptic agents in schizophrenia. Acta Psychiatr Scand 1984; 69: 162–174
   PubMed Web of Science ®Google Scholar
• Kristensen K, Cadenhead KS. Cannabis abuse and risk for psychosis in a prodromal sample. Psychiatry Res 2007; 151: 151–154
   PubMed Web of Science ®Google Scholar
• Leweke F, Koethe D, Gerth C. Cannabidiol as an antipsychotic: A double-blind, controlled clinical trial of cannabidiol versus amisulpiride in acute schizophrenia. Paper presented at the Fifteenth Annual Symposium on Cannabinoids. Cannabinoid Research Society, Clearwater Beach, FL June, 2005
   Google Scholar
• Lewis DA, Hashimoto T. Deciphering the disease process of schizophrenia: The contribution of cortical gaba neurons. Int Rev Neurobiol 2007; 78: 109–131
   PubMed Web of Science ®Google Scholar
• Lindemann E, Malamud W. Experimental analysis of the psychopathological effects of intoxicating drug. American Journal of Psychiatry 1934; 90: 853–881
   Google Scholar
• Macleod J. Cannabis use and symptom experience amongst people with mental illness: A commentary on Degenhardt et al. Psychol Med 2007; 37: 913–916
   PubMedGoogle Scholar
• Maj PF, Collu M, Fadda P, Cattaneo A, Racagni G, Riva MA. Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1-naphthalenylmethanone. European Journal of Neuroscience 2007; 25: 3305–3311
   PubMed Web of Science ®Google Scholar
• Millman RB, Sbriglio R. Patterns of use and psychopathology in chronic marijuana users. Psychiatr Clin North Am 1986; 9: 533–545
   PubMedGoogle Scholar
• Misner DL, Sullivan JM. Mechanism of cannabinoid effects on long-term potentiation and depression in hippocampal CA1 neurons. Journal of Neuroscience 1999; 19: 6795–6805
   PubMed Web of Science ®Google Scholar
• Miyamoto A, Yamamoto T, Ohno M, Watanabe S, Tanaka H, Morimoto S, et al. Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Res 1996; 710: 234–240
   PubMedGoogle Scholar
• Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, et al. Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet 2007; 370: 319–328
   PubMed Web of Science ®Google Scholar
• Moreau J. Hashish and mental illness. Raven Press, New York 1973
   Google Scholar
• Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. British Journal of Psychiatry 2008; 192: 306–307
   PubMed Web of Science ®Google Scholar
• Munafo MR, Attwood AS, Flint J. Neuregulin 1 genotype and schizophrenia. Schizophr Bull 2008; 34: 9–12
   PubMedGoogle Scholar
• Murray RM, Morrison PD, Henquet C, Di Forti M. Cannabis, the mind and society: The hash realities. Nat Rev Neurosci 2007; 8: 885–895
   PubMed Web of Science ®Google Scholar
• Negrete JC, Knapp WP, Douglas DE, Smith WB. Cannabis affects the severity of schizophrenic symptoms: Results of a clinical survey. Psychol Med 1986; 16: 515–520
   PubMed Web of Science ®Google Scholar
• ONDCP. Marijuana: The greatest cause of illegal drug abuse. The marijuana factbook. Office of National Drug Control Policy, Executive Office of the President, Washington, DC 2008
   Google Scholar
• Pillay SS, Rogowska J, Kanayama G, Gruber S, Simpson N, Pope HG, et al. Cannabis and motor function: fMRI changes following 28 days of discontinuation. Exp Clin Psychopharmacol 2008; 16: 22–32
   PubMedGoogle Scholar
• Pistis M, Porcu G, Melis M, Diana M, Gessa GL. Effects of cannabinoids on prefrontal neuronal responses to ventral tegmental area stimulation. Eur J Neurosci 2001; 14: 96–102
   PubMed Web of Science ®Google Scholar
• Pope HG, Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: What is the nature of the association?. Drug Alcohol Depend 2003; 69: 303–310
   PubMed Web of Science ®Google Scholar
• Pope HG, Jr, Gruber AJ, Hudson JI, Huestis MA, Yurgelun-Todd D. Neuropsychological performance in long-term cannabis users. Arch Gen Psychiatry 2001; 58: 909–915
   PubMed Web of Science ®Google Scholar
• Ranganathan M, D'Souza DC. The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology (Berlin) 2006; 188: 425–444
   PubMed Web of Science ®Google Scholar
• Reefer Madness. Dir. Gasnier, L.J. Perf. Craig, K. and Harvey, H. Jr. Motion Picture Ventures, 1936.
   Google Scholar
• Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: Characteristics of users in an Australian rural area. Addiction 1998; 93: 837–846
   PubMed Web of Science ®Google Scholar
• Robbe D, Alonso G, Duchamp F, Bockaert J, Manzoni OJ. Localization and mechanisms of action of cannabinoid receptors at the glutamatergic synapses of the mouse nucleus accumbens. Journal of Neuroscience 2001; 21: 109–116
   PubMedGoogle Scholar
• Robbe D, Montgomery SM, Thome A, Rueda-Orozco PE, McNaughton BL, Buzsaki G. Cannabinoids reveal importance of spike timing coordination in hippocampal function. Nat Neurosci 2006; 9: 1526–1533
   PubMed Web of Science ®Google Scholar
• Schiffman J, Nakamura B, Earleywine M, LaBrie J. Symptoms of schizotypy precede cannabis use. Psychiatry Res 2005; 134: 37–42
   PubMedGoogle Scholar
• Schweinsburg AD, Nagel BJ, Schweinsburg BC, Park A, Theilmann RJ, et al. Abstinent adolescent marijuana users show altered fMRI response during spatial working memory. Psychiatry Res 2008; 163: 40–51
   PubMed Web of Science ®Google Scholar
• Skosnik PD, Spatz-Glenn L, Park S. Cannabis use is associated with schizotypy and attentional disinhibition. Schizophr Res 2001; 48: 83–92
   PubMed Web of Science ®Google Scholar
• Sneider JT, Pope HG, Jr, Silveri MM, Simpson NS, Gruber SA, Yurgelun-Todd DA. Differences in regional blood volume during a 28-day period of abstinence in chronic cannabis smokers. European Neuropsychopharmacol 2008; 18: 612–619
   PubMed Web of Science ®Google Scholar
• Solowij N. Do cognitive impairments recover following cessation of cannabis use?. Life Sci 1995; 56: 2119–2126
   PubMed Web of Science ®Google Scholar
• Solowij N, Stephens RS, Roffman RA, Babor T, Kadden R, Miller M, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. Journal of the American Medical Association 2002; 287: 1123–1131
   PubMed Web of Science ®Google Scholar
• Stirling J, Barkus EJ, Nabosi L, Irshad S, Roemer G, Schreudergoidheijt B, et al. Cannabis-induced psychotic-like experiences are predicted by high schizotypy. Confirmation of preliminary results in a large cohort. Psychopathology 2008; 41: 371–378
   PubMedGoogle Scholar
• Stone JM, Morrison PD, Pilowsky LS. Glutamate and dopamine dysregulation in schizophrenia – A synthesis and selective review. Journal of Psychopharmacology 2007; 21: 440–452
   PubMed Web of Science ®Google Scholar
• Takahashi KA, Castillo PE. The CB1 cannabinoid receptor mediates glutamatergic synaptic suppression in the hippocampus. Neuroscience 2006; 139: 795–802
   PubMed Web of Science ®Google Scholar
• Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 1997; 276: 2048–2050
   PubMed Web of Science ®Google Scholar
• Tennant FS, Jr, Groesbeck CJ. Psychiatric effects of hashish. Arch Gen Psychiatry 1972; 27: 133–136
   PubMed Web of Science ®Google Scholar
• Veling W, Mackenbach JP, van Os J, Hoek HW. Cannabis use and genetic predisposition for schizophrenia: A case-control study. Psychol Med 2008; 38: 1251–1256
   PubMed Web of Science ®Google Scholar
• Verdoux H, Gindre C, Sorbara F, Tournier M, Swendsen JD. Effects of cannabis and psychosis vulnerability in daily life: An experience sampling test study. Psychol Med 2003; 33: 23–32
   PubMed Web of Science ®Google Scholar
• Warnock J. Insanity from hasheesh. Journal of Mental Science 1903; 49: 96–110
   Google Scholar
• Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: Historical cohort study. British Medical Journal 2002; 325: 1199
   PubMed Web of Science ®Google Scholar
• Zuardi AW, Hallak JE, Dursun SM, Morais SL, Sanches RF, Musty RE, et al. Cannabidiol monotherapy for treatment-resistant schizophrenia. J Psychopharmacol 2006; 20: 683–686
   PubMed Web of Science ®Google Scholar